BACM
GILD icon

Blue Arrow Capital Management’s Gilead Sciences GILD Stock Holding History

Blue Arrow Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,823
Closed -$473K – 156
2015
Q1 		$473K Buy
4,823
+2,668
+124% +$271K 0.05% 145
2014
Q4 		$203K Sell
2,155
-6,702
-76% -$693K 0.02% 173
2014
Q3 		$943K Sell
8,857
-16,143
-65% -$1.58M 0.1% 151
2014
Q2 		$2.07M Buy
+25,000
New +$1.95M 0.28% 85

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Blue Arrow Capital Management's GILD Position: Q2 2015 in Review

Blue Arrow Capital Management sold out of Gilead Sciences (GILD) in Q2 2015, closing a stake of 4,823 shares — an estimated $473K sold.

Blue Arrow Capital Management first reported a position in GILD in Q2 2014 and held it in 4 quarters. The position peaked at $2.07M in Q2 2014. 1,560 funds tracked by Wall St. Rank hold GILD as of Q2 2015.

  • Blue Arrow Capital Management reported no remaining Gilead Sciences position as of Q2 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 4,823 Gilead Sciences shares in Q2 2015, an estimated $473K.
  • Blue Arrow Capital Management first reported a position in Gilead Sciences in Q2 2014 and held it in 4 quarters.
  • Blue Arrow Capital Management's Gilead Sciences position peaked at $2.07M in Q2 2014.
  • 1,560 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2015.

Based on Blue Arrow Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.